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β-Thalassemia/HbE is highly prevalent in Southeast Asian countries, especially 
Thailand. It is a severe hereditary anemia disease involving ineffective erythro-
poiesis in the bone marrow and peripheral tissues. The excess of alpha globin and 
iron overload contribute to elevated oxidative damages leading to a premature cell 
death of erythroid cells and a diminished terminal differentiation of reticulocytes. 
Although proteomic approach would gain a comprehensive picture of the complex 
pathophysiology of human bone marrow and hematopoietic stem cells (HSCs), 
obtaining sufficient clinical specimens remains an important issue. The employ-
ment of mass spectrometry (MS)-based proteomic profiling could overcome these 
constrains and provide useful insights into the cellular constituents and microen-
vironment in bone marrow milieu. In this chapter, we summarize the comparative 
proteomic studies analyzing CD34+/HSCs and bone marrow niche proteins. Under 
ineffective erythropoiesis, in-depth analyses of various proteome profiles revealed 
many of which have putative functions. Importantly, dysregulated cell death 
and survival signaling pathways could explain the deleterious pathogenesis of 
β-thalassemia/HbE.
Keywords: β-thalassemia/HbE, hematopoietic stem cells (HSCs),  
ineffective erythropoiesis and proteomics
1. Introduction
Erythrocytes contain the hemoglobin (Hb) protein that carries oxygen from the 
lungs to the rest of the body. During the development, the hemoglobin structure 
gradually changes. The fetal hemoglobin HbF (α2γ2) is a major hemoglobin in the 
human fetus during the last 7 months of development in the uterus. The adult 
hemoglobin contains two components, the major hemoglobin, Hb A (α2β2), and 
the minor hemoglobin, Hb A2 (α2δ2) [1, 2]. The composition of heme and het-
erodimeric forms of globin protein, α-globin and β-globin, is encoded by the α gene 
and the β gene, which are in chromosome 16 and 11, respectively. The inherited 
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hemoglobin disorder is a common monogenic disease that could be identified into 
two main groups, the hemoglobinopathy which is abnormal structure hemoglobin 
variants and the recessive inheritance allele which is the defective hemoglobin 
production, the thalassemia syndromes [3, 4]. More than 200 point mutations and 
80 different deletions within the β-globin-encoding gene are related to inherited 
hemoglobin disorder of β-thalassemia that represent in population worldwide 
[5]. In Southeast Asia, especially Thailand, hemoglobin E (HbE) thalassemia 
accounts for about one-half of all cases, with the highest frequencies observed. 
Approximately 35,000 patients are living with β-thalassemia syndrome in Thailand, 
7% with a β-thalassemia trait, and 17% with an HbE trait within a population of 
65 millions of Thai people [6].
Pathophysiology of β-thalassemia/HbE is strongly associated with the excess 
of unmatched α-globin chain and mutation of hemoglobin variants which are 
apparently observed inside the bone marrow, as well as peripheral tissues includ-
ing the liver and spleen [7, 8]. These phenomena are believed to be the etiological 
factors of ineffective erythropoiesis. However, these conditions are found in certain 
hereditary blood disorders and are often associated with β-thalassemia/HbE [9]. 
This disease is characterized by apoptosis of erythroid precursors and inhibited 
erythroid differentiation and maturation [10]. These lead to an insufficient number 
of red blood cells. Consequently, a decreased oxygen-carrying capacity of the blood 
is tightly linked to the compensatory mechanism of the elevated erythropoietin 
(EPO) production that later causes the deleterious effects [11].
Erythropoiesis is a complex orchestrated process involving self-renewal, pro-
liferation, differentiation, and mobilization of HSCs that gives rise to erythroid 
lineages [12]. These processes are governed by heterogeneous regulatory factors, 
cytokines, signaling molecules, and various cellular interactions. Erythropoiesis is 
extensively studied in mice model, although there are several species-specific dif-
ferences of erythroid differentiation [13]. Many in vitro studies focused on cultures 
of human hematopoietic stem cells (HSCs), and erythroid progenitor cells have 
been elucidated the pathogenesis of β-thalassemia/HbE [14–20]. However, studying 
of homeostatic imbalance inside the bone marrow regarding ineffective erythropoi-
esis is challenged by limited human samples.
The emergence of “OMIC” approach, especially proteomics, has accelerated our 
understanding of pathobiology of the β-thalassemia/HbE disease, which will have a 
substantial impact in medicine. Technological advances of proteomic analysis tools, 
for example, mass spectrometry, allow high sensitivity, reduced sample require-
ment, increased throughput, and dissect posttranslational modifications of limited 
clinical specimens [21, 22]. The use of these technologies continues to expand 
substantially, particularly to meet the need for better diagnostics and to shorten 
timeline of effective therapy development. Interestingly, in combination with 
optimized ex vivo HSCs to erythroid culture or freshly isolated samples, MS-based 
proteomic approach has revealed a more comprehensive understanding of ineffec-
tive erythropoiesis in β-thalassemia/HbE.
2. Pathophysiology of β-thalassemia/HbE
β-Thalassemia is characterized by insufficient β-globin chain production due 
to decreased production (β+) or null production (β0) of β-globin chain, which is 
the main component of adult hemoglobin. This condition leads to variable clinical 
symptoms. β-Thalassemia major is characterized by severe anemia. Individuals with 
homozygous β-thalassemia may develop β-thalassemia major or β-thalassemia inter-
media. The concentration of hemoglobin could distinguish types of β-thalassemia 
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[3, 4, 23, 24]. β-Thalassemia major has low levels of hemoglobin of 3–4 g/dL, 
whereas the mild-to-moderate anemia show hemoglobin concentration at 7–10 g/dL.  
Clinical complications of β-thalassemia major include growth retardation, pallor, 
jaundice, poor musculature, genu valgum, hepatosplenomegaly, and leg ulcers. 
A severe anemia is accompanied by ineffective erythropoiesis with bone expan-
sion and extramedullary erythropoiesis in the liver, spleen, and other sites such as 
paravertebral masses. These lead to the skeletal changes including deformities in the 
long bones of the legs and typical craniofacial changes [3, 25]. Typical treatment for 
β-thalassemia major is primarily blood transfusion which causes another complica-
tion, posttransfusional iron overload. In some cases, chelation therapy could be 
implemented.
β-Thalassemia/HbE has extremely diverse clinical phenotypes because of vari-
ous genetic lesions of the gene affecting different impaired globin chain synthesis 
and abnormal forms of hemoglobin variants [3, 4]. The genetic mutation of the 
β-globin-encoding gene at codon 26 (GAG to AAG) contributes to the activation of 
cryptic splice site that cause abnormal mRNA processing. The βE-chain are pro-
duced at a reduced level resulting in a mild β-thalassemic phenotype [26]. Each year 
in Thailand, approximately 3000 infants are born with β-thalassemia/HbE either a 
mild β-thalassemia or a severe transfusion-requiring β-thalassemia major. HbE/β-
thalassemia patients have remarkable variation in terms of severity reflecting the 
heterogeneity of the β-thalassemic mutations in the HbE gene and other modulation 
factors. Newborns carrying HbE/β-thalassemia mutations are usually asymptomatic 
because they rely on the HbF hemoglobin rather than the HbE. After 6–12 month 
of birth, anemia with abdominal enlargement due to hepatosplenomegaly could be 
observed [27–30]. Although the defect in β-globin production could be explained 
by the mutations or the absence of the β-globin gene or other modification fac-
tors, the variable severity of β-thalassemia is also involved in an imbalance of 
β- and α-chains, particularly in maturing erythroid cells [31]. The accumulating 
unmatched free α-globin chain is unstable and could precipitate in the erythroid 
precursors in the bone marrow as well as in peripheral blood. A severe accumulation 
of the α-chain forms hemichromes which cause uncontrollable oxidative damages 
in erythroid precursor and erythroid cells. The hemichromes can generate reactive 
oxygen species (ROS) that potentially damage important proteins, DNA, and other 
cellular components and trigger signaling cascades of programmed cell death  
[10, 32–36]. The destruction of erythroid cells is an onset of dramatic amelioration 
cycles inside the bone marrow and peripheral organ due to the ineffective erythro-
poiesis in β-thalassemia/HbE patients.
3. Ineffective erythropoiesis
Erythropoiesis is a progressive orchestrated process involving heterogeneous 
regulatory factors such as cytokines, signaling molecules, and various cellular inter-
actions which play important roles in self-renewal, proliferation, differentiation, and 
mobilization of HSCs to become erythroid lineage [13, 37]. The ineffective erythro-
poiesis is the hallmark pathophysiological condition having seen in β-thalassemia/
HbE. In β-thalassemia/HbE, the oxidative damage caused by the accumulation of 
hemichromes and the generation of ROS in red blood cells (RBCs) and erythroid 
progenitors are an etiologic factor perturbing the homeostasis of erythropoiesis [8]. 
In vitro and in vivo studies of mice model and ex vivo studies of human HSCs and 
erythroid progenitors have elucidated the molecular pathogenesis of the ineffective 
erythropoiesis of β-thalassemia. The excess of α-chain is believed to accelerate apop-
totic cell death in erythroid precursors [10], while the inhibited processes involving 
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differentiation of erythroid maturation have been observed during polychromato-
philic stage [34]. Both detrimental processes lead to an insufficient number of RBCs 
and decreased oxygen-carrying capacity of blood and ultimately cause hypoxia 
condition. The lack of mature RBCs stimulates a compensatory mechanism of eryth-
ropoiesis that triggers the overproduction of EPO from the kidney. The increased 
EPO could induce erythropoiesis in the bone marrow by inducing proliferation of 
HSCs and erythroid progenitors. The EPO also triggers survival mechanism under 
stress condition and supports differentiation of mature RBCs. However, the dramatic 
oxidative damages inside the bone marrow are the key factor that generates a homeo-
static imbalance of erythropoiesis. This is linked to an erythroid expansion leading to 
extramedullary hematopoiesis [37]. Dysregulated hemoglobin synthesis and hemo-
lysis are major factors of the ineffective erythropoiesis and determine the severity of 
the disease [38]. Another clinical complication is an iron overload in severe patients 
that are treated by regular blood transfusions which is not required for thalassemia 
intermedia patients. Blood transfused patients usually develop elevated body iron 
load due to an increased gastrointestinal iron absorption. Consequently, the accu-
mulation of iron also causes oxidative stress because they produce highly reactive 
hydroxyl radicals that could not be naturally degraded by enzymatic reaction. 
Altogether, the accumulation of unstable free α-globin, heme, and iron all contrib-
utes to destruction of cellular compartments in the bone marrow of β-thalassemia 
patients [7, 39, 40]. Previous studies attempted to identify molecular and cellular 
mechanisms associated with the ineffective erythropoiesis in β-thalassemia patients. 
However, the bone marrow is tightly linked to other vital organs and complicates the 
deciphering of ineffective erythropoiesis of β-thalassemia.
Although there are well-established genetic manipulation techniques in model 
organisms such as mice and zebrafish and extensive enrichment methods of specific 
cell stage of hematopoietic progenitors make functional study of hematopoiesis 
possible, many components of the process act differently in human due to the 
evolutionary distance of hematopoietic genes, transcription, and epigenetic regula-
tions [13]. Ex vivo human model using primary cell cultures of HSCs obtained from 
the peripheral blood, cord blood, and bone marrow or fetal liver of donor remains 
a gold standard of erythropoiesis study. Notably, involving multifactors could be 
determined in very proliferated and differentiated cells in different culture systems 
[41]. However, in expansion and differentiation steps, primary cell culture system 
may not provide sufficient amounts of analytes for some downstream techniques 
such as Western blot. While most techniques have their limitation to systemati-
cally analyze the bone marrow, its microenvironment and other neighboring 
cellular interactions during pathological conditions of ineffective erythropoiesis of 
β-thalassemia/HbE. Alternative approaches could be implemented to analyze the 
limited isolated primary cells of thalassemia patients and potentially other dys-
erythropoietic diseases. Here, we discuss advantages of OMIC approaches especially 
proteomics for studying molecular pathogenesis of β-thalassemia/HbE.
4. Clinical proteomics of β-thalassemia/HbE
One of the goals of proteomic study is to characterize the flow of information 
through complex protein networks in a particular disease model, where the changes 
of proteins in the whole proteome can be identified in the pathophysiological condi-
tions at different disease developmental stages. Comparative proteome profiling 
of patient and healthy subjects may help to provide new clinical conceptualization 
for systemic pathophysiology including root causes, biomarkers, and applicable 
treatment regimes. Clinical proteomics is an exciting sub-discipline of proteomics 
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that will integrate the application of proteomic technology to identify problems at 
the bedside [42]. Conventional analysis methods, such as Western blot, are difficult 
because of limited amounts of clinical samples in many disease models. In the field 
of biomedical research, nonetheless, the cause of the disease could not be thor-
oughly explained due to the complexity of various molecular and cellular pathways 
in many types of cells and tissues. Therefore, elucidation of protein network 
alteration in clinical samples is an advantage strategy for deciphering interaction 
between proteins and their expression profiles which are related to cellular physiol-
ogy [43]. Despite high-throughput genomic technology can identify differential 
gene expression in disease samples, proteome alterations still occur in many ways 
not predictable from genomic analysis. A better understanding of these alterations 
will have a substantial impact in medicine [44, 45]. Moreover, clinical proteomic 
is a very promising tool for identifying various posttranslational modifications, 
such as phosphorylation and glycosylation. The recent advance proteomic analysis 
provides high sensitivity, reduced sample requirement, increased throughput, and 
is able to uncover various posttranslational modifications which are available for 
disease-related applications [46]. The use of these technologies will likely expand 
substantially, particularly to meet the need for better diagnostics and to shorten the 
path for developing effective therapy.
Proteomic analysis of blood samples has become an interesting method in 
hematological studies. The extremely rich spectrum of proteins in blood and blood 
components serves various cellular activities including coagulation, transport, 
immune system and cell signaling, as well as by-products of cellular damage and 
proteins from other tissues [47]. Whereas, the identification of originality related 
hematopoiesis from HSCs in some clinical respects such as leukemia and anemia are 
very challenging [48]. Since the key candidate proteins belonging to any disease sta-
tus are in the low-abundance level, to overcome these problems, protein samples are 
fractionated to allow effective detection and quantification by mass spectrometry 
(MS) [21]. Different protein separation methods influence MS results. Many previ-
ous clinical proteomic studies of β-thalassemia/HbE employed gel-based technique 
and shotgun proteomic to analyze posttranslational modifications of the thalas-
semic proteome. Most comparative protein profiles of β-thalassemia/HbE between 
patients with normal subjects from various types of clinical specimens including 
plasma serum, platelets, platelet-free plasma-derived microvesicles, and circulating 
extracellular vesicles (EVs) have been reported [49, 50]. Interestingly, a few studies 
have directly investigated proteomic changes inside the bone marrow or isolated the 
HSCs of thalassemic samples, where are the major site of erythropoiesis and could 
identify relevant proteins in the ineffective erythropoiesis. HSCs were isolated from 
bone marrow cells and peripheral blood using antibody specific to CD34, the trans-
membrane glycoprotein. Both peripheral blood- and bone marrow-derived CD34+/
HSCs showed differentially regulated proteomes during ineffective erythropoiesis 
in β-thalassemia/HbE [15, 18]. Recently reports have revealed the nature of the bone 
marrow plasma proteome and the roles of microenvironment in the bone marrow 
niche and linked to the dyserythropoiesis of β-thalassemia/HbE [51].
4.1 Gel-based technique
Gel-based proteome analysis method involves a separation of proteins using 
either one-dimensional (1-D) or two-dimensional electrophoresis (2-DE). Since 
2-DE separates proteins by their isoelectric points and by molecular weight, it is a 
standard choice for protein separation. After the proteins are resolved, the gel is 
visualized by staining with visible dyes, such as Coomassie Blue or silver nitrate 
or with fluorescent dyes such as Sypro Ruby. The gel is imaged and analyzed by 
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software to identify protein spot that show altered intensity. Selected protein spots 
are excised and subjected to in-gel digestion typically by trypsin, resulting in 
peptides that can be further analyzed by mass spectrometry (MS) or tandem mass 
spectrometry (MS/MS). One of the drawbacks of the conventional 2-DE is gel-to-
gel variability. For many proteomic studies, multiple gels of many samples have to 
be run, and spots at a certain location have to match between gels to reduce variabil-
ity, but this still cannot fully eliminate the problem. Apart from variability, 2-DE 
also has poor reproducibility and provides relatively lower sensitivity. To circum-
vent these problems, two-dimensional difference gel electrophoresis (2-DIGE) has 
been developed. By labeling different samples with different fluorescent dyes and 
separating them in the same gel, 2-DIGE enables better comparison of up to three 
protein samples [22, 52, 53]. However, there are some proteins cannot be resolved 
on 2-D gels due to their physicochemical properties. These include highly basic or 
acidic proteins, proteins with extremely high or low molecular weight, and mem-
brane proteins that are inherently insoluble in gel matrices [21].
Two-dimensional gel electrophoresis (2-DE) coupled with mass spectrometry 
or tandem mass spectrometry (MS and MS/MS) has been used for the investiga-
tion of β-thalassemic proteomes. The majority of differential expressed proteins 
between β-thalassemia patients and normal clinical specimens have been identified 
and characterized their functions in different metabolic processes in response to 
inorganic substances using an online DAVID gene ontological analysis [54]. Several 
enzymes in metabolic processes are usually abundant and easily found on the 2-DE, 
whereas low-abundant proteins involve in gene regulation and signal transduction 
cascades are difficult to detect. However, 1D-SDS-PAGE may be used as a standard 
separation method for complex protein mixtures based on their molecular weight 
prior MS analysis. Gel-enhanced liquid chromatography coupled with tandem mass 
spectrometry (GeLC-MS/MS) is a direct intensive methodology that provides high 
coverage of the proteome. GeLC-MS/MS is applicable to reduce gel-to-gel variation 
and inconsistency of protein spots in a 2-DE and to increase sensitivity of detection 
of low-abundant proteins [55]. Current study of bone marrow plasma proteome 
profile using GeLC-MS/MS technique has reported differentially expressed proteins 
between patients and normal donors and showed that many of which have func-
tions in intracellular signaling and metabolic pathways associated with ineffective 
erythropoiesis [51]. GeLC-MS/MS has been used to analyze the CD34+/HSCs’ 
thalassemic proteome during the in vitro differentiation of erythroid lineages and 
identified dysregulation of many signaling protein of differentiation processes in 
thalassemia patients (unpublished data).
4.2 LC-based technique
LC-based technique or shotgun proteomic analysis is an advanced and widely 
used approach for protein identification and characterization of sequence variants 
and posttranslational modifications [56]. Shotgun proteomics is considered as a 
bottom-up approach, by which short peptides are prepared by proteolytic diges-
tion, usually by trypsin, and subjected to protein sequencing via tandem mass 
spectrometry (MS/MS) and automated protein database searching. After proteo-
lytic digestion by trypsin, short peptide mixture is fractionated by hydrophobicity 
and charged using multidimensional liquid chromatography. Eluted peptides 
from the column are then ionized and separated by m/z in the first stage of MS/
MS. Fragmentation is initiated when the peptide ions undergo collision-induced 
dissociation (CID) within inert gas. The ionized fragments are then separated by 
m/z in the second stage of MS/MS, and the corresponding peptide ions generate 
fragment ion spectral fingerprints for peptide identification. The process continues 
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until all peptides are eluted from the chromatography column. Peptide identifica-
tion is accomplished by comparing the fragmentation spectra derived from peptide 
fragmentation with theoretical MS/MS spectra based on in silico protein database. 
Protein inference is achieved by allocating peptide sequences to proteins [56–58]. 
Shotgun proteomics has a relatively high throughput compared to other MS-based 
proteomic technologies. This gel-free approach involves proteolytic digestion of 
proteins into short peptides (1–3 kDa) as they are easier to fragment than intact 
proteins simplifying MS/MS sequencing [21].
Erythropoiesis involves posttranslational modifications of proteins associ-
ated with cell-cell communications and cell interactions inside the bone marrow. 
Phosphorylation is mediated by kinase enzymes which have different target speci-
ficities. Different phosphorylation sites on the same protein usually serve different 
protein activities. Shotgun proteomic strategy becomes the widely used for study-
ing phosphoproteomes. The CD34+/HSCs’ isolation from the bone marrow is a good 
representative model for elucidation signaling proteins using phosphoproteomic 
analysis comparing with thalassemia patient and normal donor. The workflow 
includes an enrichment of phosphoproteins among patient and donor samples using 
immobilized metal affinity chromatography (IMAC), followed by ESI-LC-MS/
MS. This approach detects upregulation of signaling proteins of apoptosis pathway 
linked to ineffective erythropoiesis in β-thalassemic CD34+/HSCs [15].
5.  Alteration of proteome profiles in hematopoietic stem cells (HSCs) 
derived from β-thalassemia/HbE patients
The hallmarks of stem cells include self-renewal and differentiation ability to 
give rise different types of mature cells. Stem cell biology is an important field of 
biomedical science and holds promise in clinical applications. The hematopoietic 
stem cells (HSCs) are multipotent progenitor cells located in adult bone marrow, 
responsible for blood cell production. Multipotency or multi-lineage differentiation 
potential of the HSCs defines as the capacity to give rise to several differentiated 
cell types including myeloid progenitor cells, erythroid-megakaryocyte progenitor 
cells, and lymphoid progenitor cells [13]. In addition, the proliferation and dif-
ferentiation of HSCs into the erythroid lineage are the acquisition of functional and 
structural properties associated with erythrocyte physiology [37, 59]. The cell isola-
tion technique of the primitive HSCs’ population expressing specific cell surface 
markers, CD34 and CD133, is a gold standard method widely used for investigating 
of erythropoiesis in vivo [60]. Using antibody-conjugated magnetic particles is the 
first step after the isolation of mononuclear cells from bone marrow aspirate or 
from peripheral blood. Optimized culture condition for in vivo erythroid develop-
ment requires defined medium supplemented with cytokines, such as erythropoi-
etin (EPO), to modulate erythroid cell development from HSCs/CD34+. Erythroid 
differentiation is a multistep process starting when a subset of HSCs/CD34+ com-
mits to differentiate to the megakaryocyte-erythrocyte progenitors (MEPs). The 
differentiation of MEPs into the most immature erythroid progenitors, namely, a 
burst-forming unit erythroid (BFU-Es), involves a number of transcriptional regu-
lators. The BFU-Es generate colony-forming units-erythroid cells (CFU-Es) which 
strictly depends on the erythropoietin to induce differentiation via erythropoietin 
receptor (EPOR). Subsequently, the CFU-Es develop into proerythroblasts (the 
first erythroid precursors) through the basophilic, the polychromatophilic, and the 
orthochromatic stages. During this differentiation process, the hemoglobin synthe-
sis, cellular content modification, and nuclear condensation gradually take place, 
followed by the enucleation step generating reticulocytes which are immature red 
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blood cells (RBCs). In addition to the macrophage-induced cellular death pathways, 
autophagy is the key mechanism of the biconcave formation of mature RBCs [13]. 
Conversely, in β-thalassemia/HbE patients, the ineffective erythropoiesis has dra-
matic effects in the erythroid lineage development, resulting in hyperproliferation, 
increased apoptosis, and inhibited terminal erythroid differentiation. To study the 
pathogenesis of β-thalassemia/HbE, our strategies include the isolation of CD34+/
HSCs, in vitro erythroid differentiation, and bone marrow plasma enrichment fol-
lowed by the MS-based analysis to comprehensively understand the early molecular 
basis of β-thalassemia/HbE. This method revealed the bona fide proteome altera-
tions of ineffective erythropoiesis from CD34+/HSCs, the dynamic differentiation 
of CD34+/HSCs in the erythroid lineage, and bone marrow microenvironment 
(Figure 1A). The bioinformatic approach has also been applied to analyze inte-
grated thalassemia-specific proteomes in a range of patient specimens. We report 
interesting imbalance signaling landscapes which may contribute to ineffective 
erythropoiesis found in β-thalassemia/HbE patients.
5.1 Metabolic enzymes
Leecharoenkiat et al. reported the first differential 2-DE proteome between β0-
thalassemia/HbE and control erythroblasts isolated from peripheral CD34+/HSCs. 
Many differentially expressed proteins identified in this study were constituents of 
the glycolysis and TCA pathways and were correlated with the degree of erythroid 
expansion [18]. Our investigation of bone marrow microenvironment proteome has 
shown increased level of ATP citrate lyase (ACLY) in β-thalassemia patients. ACLY 
is primarily responsible for synthesis of acetyl CoA in TCA cycle. Consequentially, 
hyperproliferation of erythroblast during ineffective erythropoiesis might be 
related with the increase of ACLY indicating a high metabolic flux governed by 
acetyl-CoA production. ACLY can support sufficient energy to drive the TCA cycle 
and mitochondrial oxidative phosphorylation [51]. Therefore, the comparative 
proteome profiling of peripheral blood CD34+/HSCs and bone marrow plasma 
proteome indicated the similar target metabolic protein biomarkers associated with 
ineffective erythropoiesis.
5.2 Oxidative damage and antioxidant proteins
An imbalance between oxidative damage and antioxidant enzymes is associ-
ated with cellular pathology inside HSCs and differentiated erythroid precursors 
in β-thalassemia patients. Comparative proteome analysis during differentiation 
of CD34+/HSCs through erythroid lineage for 7 days in β-thalassemia patients 
compared with normal showed many proteins differentially expressed; these 
include superoxide dismutase (SOD), peroxiredoxin 6 (PXD6), and peroxiredoxin 
2 (PXD2). An increased level of PXD2 was found in differentiated thalassemic 
CD34+/HSCs at day 0 through day 7 (unpublished data). In addition, PXD2 has 
function in stress response in the protective system during stress erythropoiesis 
in thalassemic mice model [61]. PXD2 is an abundant protein mostly identified in 
many proteomic studies from various clinical specimens of β-thalassemia  
[50, 54, 62]. An increased oxidative damage from alpha excess and iron overload 
thus triggers the cellular defensive mechanism, including antioxidative responses. 
Nevertheless, thalassemic stem cells could not prolong survival pathways to prevent 
cell death. Moreover, comparative bone marrow plasma proteome from patients and 
normal showed a decreased level of an antioxidant secretory or extracellular exo-
somal protein, namely, apolipoprotein D (ApoD), in patients who have an impair-
ment of bone marrow microenvironment to dyserythropoietic condition [51].
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5.3 Heat shock protein
Recent studies have suggested that the molecular chaperone or the heat shock 
protein maintains cellular homeostasis during erythropoiesis. Regulated by the 
GATA-1, the master transcriptional machinery of erythropoiesis, the heat shock 
Figure 1. 
Diagram showed the sample preparation from bone marrow-derived CD34+/HSCs and bone marrow 
plasma prior to MS-based proteomic approaches. The three sources of proteomes for investigating ineffective 
erythropoiesis include CD34+/HSCs’ phosphoproteome, dynamic differential proteome during erythroid 
development, and bone marrow plasma proteome (A). Schematic diagram of identified proteins and proposed 
signaling pathway for ineffective erythropoiesis in β-thalassemia/HbE (B).
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protein 70 (HSP70) plays an important role in protecting from caspase-3-mediated 
GATA-1 degradation [63]. Conversely, in β-thalassemia major, the alleviated free 
alpha globin exacerbates the oxidative damage inside erythroblast which induces 
the translocation of heat shock protein 70 from the nucleus to cytoplasm, leaving 
GATA1 unprotected [63]. The expression of heat shock protein 70 in patient group 
was dramatically significantly increased from day 0 to day 7, suggesting it as a 
contributing factor of ineffective erythropoiesis (unpublished data). Furthermore, 
the heat shock protein 90 that has a similar expression pattern as heat shock pro-
tein 70 and has been identified over expression from platelet-free plasma-derived 
microparticles proteome in β-thalassemia/HbE patients [50].
5.4 Apoptotic pathway
Erythroid progenitors undergoing terminal erythroid differentiation to gener-
ate sufficient erythroblasts and reticulocytes are impaired during ineffective 
erythropoiesis of β-thalassemia involving the acceleration of apoptotic cell death 
in erythroid precursors. The apoptotic proteins of intrinsic and extrinsic pathways 
have been firstly identified from the phosphoproteomic analysis of β-thalassemia 
CD34+/HSCs. This might explain why even freshly isolated HSCs of β-thalassemia 
bone marrow showed less survival compared to HSCs from normal donors. 
Phosphoproteome analysis of β-thalassemia HSCs identified an increased expres-
sion of cytochrome C (CytC), apoptosis-inducing factor (AIF), and caspase 6 
(CASP6) [15]. Moreover, extrinsic apoptotic pathway plays important roles during 
erythroid differentiation rather than the progenitor or HSCs’ stages. The analysis 
of thalassemia HSCs’ phosphoproteome during in vitro differentiation to erythroid 
lineage of CD34+/HSCs revealed very high expression of death receptor proteins, 
such as TNF receptor-associated factor 2 (TRAF2), at day 7 but was undetectable at 
day 0 (unpublished data), as well as the downregulations of tumor necrosis factor 
ligand superfamily member 6 (FASL) and tumor necrosis factor receptor super-
family member 12A [15]. Thus, we propose that the imbalance of death signaling 
pathway could have a predominant effect during erythroid proliferation and differ-
entiation in β-thalassemia. However, few studies explained how ROS and oxidative 
stress are related to an ineffective erythropoiesis. It remains to investigate whether 
ROS signaling could provoke apoptotic pathway of ineffective erythropoiesis.
5.5 The AKT/FOXO3/14-3-3 axis
After the finding of the imbalance cell death protein in CD34+/HSCs’ proteomes 
from both fresh isolated and erythroid differentiated condition in vitro. The 14-3-3 
protein was found upregulated in HSCs of β-thalassemia/HbE patients. This 
identified a molecular linkage between both survival and death signaling pathways 
[15]. An elevated ROS level in β-thalassemia erythroid cells plays an important role 
in the activation of AKT, potentially resulting in the repression of FOXO3 activity 
and reducing the cellular responses to oxidative stress. Nevertheless, AKT-mediated 
FOXO3 phosphorylation at Ser253 could not maintain the activation of FOXO3 
activity to induce downstream gene expression of stress responses in β-thalassemia/
HbE [14]. This leads to a premature apoptosis of erythroid cells. In this circum-
stance, activation of AKT and the translocation of FOXO3 from the nucleus to cyto-
plasm involve the activation of 14-3-3 which binds to FOXO3 and induces FOXO3 
degradation by ubiquitination/proteasome pathway [64]. In addition to the signal-
ing crosstalk of AKT and 14-3-3 modulated FOXO3 function, c-Jun N-terminal 
kinase (JNK) pathway and other posttranslational modifications, especially acetyla-
tion, promote FOXO3 transcriptional activity inside the nucleus [64, 65]. However, 
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the regulation of 14-3-3 among AKT and JNK signaling-mediated FOXO3 function 
through involving imbalance of death and survival signaling during ineffective 
erythropoiesis remains to be investigated (Figure 1B).
6. Conclusions
Proteomic analysis by MS has become an efficient tool for investigating patho-
physiology of β-thalassemia/HbE overcoming limiting factors of stem cell samples, 
especially hematopoietic stem cells (HSCs). Integrated proteome profiling using 
shotgun-based and gel-based proteomic analyses of clinical bone marrow or periph-
eral blood samples shed light on the molecular mechanisms on ineffective erythro-
poiesis in β-thalassemia. Better understanding of these molecular mechanisms will 
help the development of novel treatment of the disease.
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